This pharma player announced a key milestone achieved by the company that will help increase its revenue and profitability. In this article, we will try to decode the information announced by the company.
Price Movement
With a market capitalization of Rs 683 crore, the shares of Sakar Healthcare Ltd is currently trading at Rs 311, down by 17 percent from its 52-week high of Rs 374.50 per share. The stock has given a negative return of 13 percent over the last one year.
About the announcement
Pharma company, Sakar Healthcare Ltd, on Monday announced that the company was granted First Marketing Authorization (MA)/Registration of Oncology Injection in the European Union (EU).
The approval, under a dossier submitted in accordance with EU guidelines, allows the company to export and market its EU GMP-approved liquid oncology formulation into the EU market. Seven more products are in the process of being registered, with approvals anticipated within the next few months, which will open up wider oncology exports to the European Union.
Also read: AI stock jumps 8% after securing multi-million dollar deal from UK-based global bank
Financial Highlights
The company reported a revenue of Rs 43.42 crore in Q3 FY25, up by 16 percent from its Q3 FY24 revenue of Rs 37.23 crore. It reported a net profit of Rs 4.53 crore, up by 118 percent, from its Q3 FY24 net profit of Rs 2.07 crore. It is currently trading at a P/E of 46.11x, higher than the industry average of 28.30x. It has an ROE and ROCE of 5.28 percent and 7.32 percent.
About the company
Sakar Healthcare Limited is an Indian pharmaceutical firm that undertakes the research, development, manufacturing, and marketing of diverse pharmaceutical products. Its product portfolio consists of liquid orals, tablets, capsules, injections (including lyophilized), and dry syrups.
Its product portfolio consists of products that cover several therapeutic areas, including anti-infectives, analgesics, antifungals, antidepressants, antihistamines, and multivitamins. The company exports its products to markets including Southeast Asia, Africa, the Middle East, and the United States.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
